慢性阻塞性肺?。╟hronic obstructive pulmonary disease，COPD）是全球第3大致死原因，有效治療COPD已成為亟需解決的醫(yī)療問題。中藥多糖因其具有免疫調(diào)節(jié)、抗炎和抗氧化等多種生物活性，在COPD治療方面?zhèn)涫荜P(guān)注。通過系統(tǒng)檢索PubMed、中國(guó)知網(wǎng)（CNKI）及Web of Science等數(shù)據(jù)庫(kù)，對(duì)近20年來(lái)中藥多糖抗COPD的臨床試驗(yàn)和臨床前實(shí)驗(yàn)研究進(jìn)行匯總、歸納和總結(jié)。中藥多糖如黃芪多糖、香菇多糖及石斛多糖等能夠顯著改善COPD患者的臨床癥狀和呼吸功能，增強(qiáng)免疫能力，降低炎癥水平。其作用機(jī)制主要涉及減輕氧化應(yīng)激損傷、調(diào)節(jié)免疫炎癥應(yīng)答、抑制氣道重塑及調(diào)節(jié)腸道菌群等方面。中藥多糖在COPD治療中展現(xiàn)出巨大的開發(fā)潛力和應(yīng)用前景，不僅拓寬了中藥多糖在傳統(tǒng)醫(yī)學(xué)中的應(yīng)用價(jià)值，同時(shí)也為促進(jìn)中藥多糖資源的開發(fā)利用和COPD的新藥研發(fā)提供了重要的參考價(jià)值。

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, making the effective treatment of this condition is an urgent medical challenge. Polysaccharides derived from traditional Chinese medicine (TCM) have gained significant attention in COPD therapy due to their immunomodulatory, anti-inflammatory, and antioxidant properties. This study conducted a systematic search of databases, including PubMed, CNKI, and Web of Science, to summarize, categorize, and synthesize clinical trials and preclinical research on the use of these polysaccharides for the treatment of COPD over the past two decades. The analysis indicated that TCM polysaccharides, such as astragalus polysaccharides, lentinan and polysaccharide of Shihu (Dendrobii Caulis), can significantly improve clinical symptoms and respiratory function in COPD patients. These polysaccharides could enhance immune capacity and reduce inflammation levels. The mechanisms of action primarily involve alleviating oxidative stress, modulating immune-inflammatory responses, inhibiting airway remodeling, and regulating gut microbiota. The TCM polysaccharides in the treatment of COPD demonstrates substantial development potential and promising prospects. This not only broadens the application value of polysaccharides in traditional medicine but also provides a significant reference for the development and utilization of TCM polysaccharide resources and the discovery of new drugs for COPD.

R285

國(guó)家自然科學(xué)基金項(xiàng)目（81872959，81373920，30801522）；四川省青年科技創(chuàng)新團(tuán)隊(duì)項(xiàng)目：（19CXTD0055）；成都中醫(yī)藥大學(xué)“杏林學(xué)者”學(xué)科人才科研提升計(jì)劃項(xiàng)目（ZYTS2019022）